Is the treatment of WHO category I tuberculosis with 2HRZE/6HE a defensible practice?
作者信息
Long R, Scalcini M
机构信息
University of Alberta, Edmonton, Canada.
出版信息
Int J Tuberc Lung Dis. 1999 Sep;3(9):747-8.
PMID:10488879
Abstract
摘要
相似文献
1
Is the treatment of WHO category I tuberculosis with 2HRZE/6HE a defensible practice?
Int J Tuberc Lung Dis. 1999 Sep;3(9):747-8.
2
Tuberculosis treatment: dangerous regimens?
Int J Tuberc Lung Dis. 2001 Jan;5(1):1-3.
3
Drug-resistant tuberculosis in the Philippines.
Int J Tuberc Lung Dis. 1999 Jul;3(7):639.
4
Two excellent management tools for national tuberculosis programmes: history of prior treatment and sputum status at two months.
Int J Tuberc Lung Dis. 1998 Mar;2(3):184-6.
5
[Short term chemotherapy of tuberculosis. Evaluation of an 18-week-long treatment including pyrazinamide (preliminary results)].
Bull Int Union Tuberc. 1978 Dec;53(4):260-1.
6
How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis.
Int J Tuberc Lung Dis. 1998 Jan;2(1):10-5.
7
Results of a 12-month regimen for drug-resistant pulmonary tuberculosis.
Int J Tuberc Lung Dis. 2002 Dec;6(12):1102-9.
8
[Therapy of tuberculosis in the adult].
Med Klin (Munich). 1995 Apr 15;90(4):229-30.
9
Modern treatment of tuberculosis.
Compr Ther. 1982 Sep;8(9):19-28.
10
[Short-course treatment of pulmonary tuberculosis: comparison with a classical standard regimen].
Bull Int Union Tuberc. 1985 Mar-Jun;60(1-2):29-30.
Zotero 插件